exposure is dependent on Kupffer cell function. Am J Physiol Gastrointest Liver Physiol 2008; 295(2):G294–304.38 38 Kwan D, Bartle WR, Walker SE. Abnormal serum transaminases following therapeutic doses of acetaminophen in the absence of known risk factors. Dig Dis Sci 1995; 40(9):1951–5.
39 39 Sarich T, Kalhorn T, Magee S, al‐Sayegh F, Adams S, Slattery J, et al. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S‐mephenytoin. Clin Pharmacol Ther 1997; 62(1):21–8.
40 40 Cook MD, Williams SR, Clark RF. Phenytoin‐potentiated hepatotoxicity following acetaminophen overdose? A closer look. Dig Dis Sci 2007; 52(1):208–9.
41 41 Suchin SM, Wolf DC, Lee Y, Ramaswamy G, Sheiner PA, Facciuto M, et al. Potentiation of acetaminophen hepatotoxicity by phenytoin, leading to liver transplantation. Dig Dis Sci 2005; 50 (10):1836–8.
42 42 Maddox JF, Amuzie CJ, Li M, Newport SW, Sparkenbaugh E, Cuff CF, et al. Bacterial‐ and viral‐induced inflammation increases sensitivity to acetaminophen hepatotoxicity. J Toxicol Environ Health A 2010; 73(1):58–73.
43 43 Tukov FF, Maddox JF, Amacher DE, Bobrowski WF, Roth RA, Ganey PE. Modeling inflammation‐drug interactions in vitro: a rat Kupffer cell‐hepatocyte coculture system. Toxicol in vitro 2006; 20(8):1488–99.
44 44 Chomchai S, Chomchai C. Being overweight or obese as a risk factor for acute liver injury secondary to acute acetaminophen overdose. Pharmacoepidemiol Drug Saf 2018; 27(1):19–24.
45 45 Makin A, Williams R. Paracetamol hepatotoxicity and alcohol consumption in deliberate and accidental overdose. QJM 2000; 93(6):341–9.
46 46 Banda PW, Quart BD. The effect of mild alcohol consumption on the metabolism of acetaminophen in man. Res Commun Chem Pathol Pharmacol 1982; 38(1):57–70.
47 47 Farinati F, Cardin R, de Maria N, Lecis PE, Della Libera G, Burra P, et al. Zinc, iron, and peroxidation in liver tissue. Cumulative effects of alcohol consumption and virus‐mediated damage‐‐a preliminary report. Biol Trace Elem Res 1995; 47 (1–3):193–9.
48 48 Ozdemir O, Boran M, Gokce V, Uzun Y, Kocak B, Korkmaz S. A case with severe rhabdomyolysis and renal failure associated with cerivastatin‐gemfibrozil combination therapy‐‐a case report. Angiology 2000; 51(8):695–7.
49 49 Ravnan SL, Locke C, Yee WP, Haase K. Cerivastatin‐induced rhabdomyolysis: 11 case reports. Pharmacotherapy 2002; 22(4):533–7.
50 50 Rodriguez ML, Mora C, Navarro JF. Cerivastatin‐induced rhabdomyolysis. Ann Intern Med 2000; 132(7):598.
51 51 Simpson S. Case reports of rhabdomyolysis associated with cerivastatin therapy. Arch Intern Med 2001; 161 (21):2630–1.
52 52 SoRelle R. Baycol withdrawn from market. Circulation 2001; 104(8):E9015–6.
53 53 Wooltorton E. Bayer pulls cerivastatin (Baycol) from market. CMAJ 2001; 165(5):632.
54 54 Shek A, Ferrill MJ. Statin‐fibrate combination therapy. Ann Pharmacother 2001; 35 (7–8):908–17.
55 55 Kaspera R, Naraharisetti SB, Tamraz B, Sahele T, Cheesman MJ, Kwok PY, et al. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis. Pharmacogenet Genomics 2010; 20 (10):619–29.
56 56 Muck W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000; 39(2):99–116.
57 57 Wang JS, Neuvonen M, Wen X, Backman JT, Neuvonen PJ. Gemfibrozil inhibits CYP2C8‐mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 2002; 30 (12):1352–6.
58 58 Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)‐mediated hepatic uptake and CYP2C8‐mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug‐drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004; 311(1):228–36.
59 59 Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002; 72(6):685–91.
60 60 Muck W. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 1998; 56 Suppl 1:15–23; discussion 33.
61 61 Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 2011; 21(5):280–8.
62 62 Lucas RA, Weathersby BB, Rocco VK, Pepper JM, Butler KL. Rhabdomyolysis associated with cerivastatin: six cases within 3 months at one hospital. Pharmacotherapy 2002; 22(6):771–4.
63 63 Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transporter‐mediated hepatic uptake as a mechanism for drug‐drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003; 304(2):610–6.
64 64 Yao Y, Toshimoto K, Kim SJ, Yoshikado T, Sugiyama Y. Quantitative analysis of complex drug‐drug interactions between cerivastatin and metabolism/transport inhibitors using physiologically based pharmacokinetic modeling. Drug Metab Dispos 2018; 46(7):924–33.
65 65 Varma MV, Lin J, Bi YA, Kimoto E, Rodrigues AD. Quantitative rationalization of gemfibrozil drug interactions: consideration of transporters‐enzyme interplay and the role of circulating metabolite gemfibrozil 1‐O‐beta‐glucuronide. Drug Metab Dispos 2015; 43(7):1108–18.
66 66 Burdette DE, Sackellares JC. Felbamate pharmacology and use in epilepsy. Clin Neuropharmacol 1994; 17(5):389–402.
67 67 Zupanc ML, Roell Werner R, Schwabe MS, O'Connor SE, Marcuccilli CJ, Hecox KE, et al. Efficacy of felbamate in the treatment of intractable pediatric epilepsy. Pediatr Neurol 2010; 42(6):396–403.
68 68 Heyman E, Levin N, Lahat E, Epstein O, Gandelman‐Marton R. Efficacy and safety of felbamate in children with refractory epilepsy. Eur J Paediatr Neurol 2014; 18(6):658–62.
69 69 Thakkar K, Billa G, Rane J, Chudasama H, Goswami S, Shah R. The rise and fall of felbamate as a treatment for partial epilepsy‐‐aplastic anemia and hepatic failure to blame? Expert Rev Neurother 2015; 15 (12):1373–5.
70 70 Dieckhaus CM, Thompson CD, Roller SG, Macdonald TL. Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem Biol Interact 2002; 142 (1–2):99–117.
71 71 Pellock JM, Brodie MJ. Felbamate: 1997 update. Epilepsia 1997; 38 (12):1261–4.
72 72 Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 1995; 45 (3 Pt 1):456–60.
73 73 Shah YD, Singh K, Friedman D, Devinsky O, Kothare SV. Evaluating the safety and efficacy of felbamate in the context of a black box warning: a single center experience. Epilepsy Behav 2016; 56:50–3.
74 74 Egnell AC, Houston B, Boyer S. in vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 2003; 305(3):1251–62.
75 75 Glue P, Banfield CR, Perhach JL, Mather GG, Racha JK, Levy RH. Pharmacokinetic interactions with felbamate. in vitro–in vivo correlation. Clin Pharmacokinet 1997; 33(3):214–24.
76 76 Kapetanovic IM, Torchin CD, Strong JM, Yonekawa WD, Lu
